Equity Profile

GSK

GSK plc

Health CarePharmaceuticals$104.7B

Jul28Tue

Pre-Earnings Brief

UpcomingQ1-2011Pre-Market9:00 AM EDT

Company Snapshot

GSK plc is a global healthcare company focused on pharmaceuticals, vaccines, and consumer health products. With a market cap of $105 billion, GSK plays a crucial role in developing treatments and vaccines that address significant health challenges worldwide.

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well GSK has managed costs and revenue.

$1.16

Revenue

Total revenue reflects the company's ability to generate sales from its products, which is critical for assessing growth.

$7.6B

Wall Street expectations, options signals, track record, and call prep available with Pro.

GSK Q1-2011 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-32.34%

Avg Stock Reaction

-0.73%

Last Quarter Recap

In the last quarter, GSK reported an EPS of $0.45, significantly missing the estimate of $0.88. The stock reacted positively the following day, gaining 2.79%, despite the disappointing earnings.

Management Promises & Guidance

Focus on improving product pipeline and R&D efficiency.
Commitment to enhancing vaccine distribution capabilities.
Plans to streamline operations to reduce costs.

Expectations

Wall Street Expectations

Analysts expect GSK to report earnings that meet or slightly exceed expectations, with a consensus EPS of $1.16 and revenue of $7.6 billion. The market is cautiously optimistic following recent product developments.

Bull Case

If GSK can deliver strong sales from its new vaccines and pharmaceuticals, it could exceed earnings expectations, leading to a positive stock reaction.

Bear Case

Conversely, if GSK fails to meet the EPS estimate or reports declining sales in key segments, it could lead to a negative market reaction.

Key Metrics to Watch

EPS

$1.16

Earnings per share is a key indicator of profitability and will show how well GSK has managed costs and revenue.

Revenue

$7.6B

Total revenue reflects the company's ability to generate sales from its products, which is critical for assessing growth.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will GSK's EPS meet or exceed the consensus estimate of $1.16?

This figure will be critical in determining investor confidence and stock performance post-earnings.

What are the sales figures for GSK's new vaccines?

Strong sales in this area could indicate successful market penetration and future growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate GSK's ability to leverage its new vaccine portfolio, which could drive higher-than-expected sales.

Supporting Evidence

Recent product launches have shown strong initial demand, which may not be fully reflected in analyst estimates.

Options pricing suggests a larger potential move than historical averages, indicating market uncertainty.

The company's commitment to improving operational efficiency could enhance margins unexpectedly.

Key Risk

If GSK's new vaccine sales exceed expectations, it could significantly alter the revenue outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating GSK's ability to rebound from previous earnings misses and capitalize on new product launches.

Bull Confirmed If

An EPS of $1.18 or higher would confirm strong operational performance and growth.

Bear Confirmed If

An EPS below $1.15 would signal ongoing challenges in revenue generation.

Pre-Earnings Positioning

Options Market

Implied Move

±10.78%

Historical Avg

±2.0%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.

Options are pricing ±10.8% while GSK has averaged ±2.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

25.7%

Calls (67K)P/C Ratio: 0.41Puts (114K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

19.80%

of float

Insider

0.06%

of float

Holders

1,142

institutions

Top Holders· as of Dec 2025

Dodge & Cox Inc.
68,517,969 sh · $3.7B
3.38%
-12.6%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If GSK beats expectations, history suggests the stock could rise, confirming a positive outlook for future growth.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

A miss could lead to a decline in stock price, as historical patterns indicate negative reactions to earnings shortfalls.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the sales performance of new vaccines.
2Any changes to guidance for the upcoming quarters.
3Details on cost management strategies.
4Insights into R&D progress and pipeline developments.
5Management's outlook on market conditions and competition.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

PreviewView

Jul27

ARLPBMO

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well GSK has managed costs and revenue.

$1.16

Revenue

Total revenue reflects the company's ability to generate sales from its products, which is critical for assessing growth.

$7.6B

Wall Street expectations, options signals, track record, and call prep available with Pro.

GSK Q1-2011 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-32.34%

Avg Stock Reaction

-0.73%

Last Quarter Recap

In the last quarter, GSK reported an EPS of $0.45, significantly missing the estimate of $0.88. The stock reacted positively the following day, gaining 2.79%, despite the disappointing earnings.

Management Promises & Guidance

Focus on improving product pipeline and R&D efficiency.
Commitment to enhancing vaccine distribution capabilities.
Plans to streamline operations to reduce costs.

Expectations

Wall Street Expectations

Bull Case

If GSK can deliver strong sales from its new vaccines and pharmaceuticals, it could exceed earnings expectations, leading to a positive stock reaction.

Bear Case

Conversely, if GSK fails to meet the EPS estimate or reports declining sales in key segments, it could lead to a negative market reaction.

Key Metrics to Watch

EPS

$1.16

Earnings per share is a key indicator of profitability and will show how well GSK has managed costs and revenue.

Revenue

$7.6B

Total revenue reflects the company's ability to generate sales from its products, which is critical for assessing growth.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will GSK's EPS meet or exceed the consensus estimate of $1.16?

This figure will be critical in determining investor confidence and stock performance post-earnings.

What are the sales figures for GSK's new vaccines?

Strong sales in this area could indicate successful market penetration and future growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate GSK's ability to leverage its new vaccine portfolio, which could drive higher-than-expected sales.

Supporting Evidence

Recent product launches have shown strong initial demand, which may not be fully reflected in analyst estimates.

Options pricing suggests a larger potential move than historical averages, indicating market uncertainty.

The company's commitment to improving operational efficiency could enhance margins unexpectedly.

Key Risk

If GSK's new vaccine sales exceed expectations, it could significantly alter the revenue outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating GSK's ability to rebound from previous earnings misses and capitalize on new product launches.

Bull Confirmed If

An EPS of $1.18 or higher would confirm strong operational performance and growth.

Bear Confirmed If

An EPS below $1.15 would signal ongoing challenges in revenue generation.

Pre-Earnings Positioning

Options Market

Implied Move

±10.78%

Historical Avg

±2.0%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.

Options are pricing ±10.8% while GSK has averaged ±2.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

25.7%

Calls (67K)P/C Ratio: 0.41Puts (114K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

19.80%

of float

Insider

0.06%

of float

Holders

1,142

institutions

Top Holders· as of Dec 2025

Dodge & Cox Inc.
68,517,969 sh · $3.7B
3.38%
-12.6%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If GSK beats expectations, history suggests the stock could rise, confirming a positive outlook for future growth.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

A miss could lead to a decline in stock price, as historical patterns indicate negative reactions to earnings shortfalls.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the sales performance of new vaccines.
2Any changes to guidance for the upcoming quarters.
3Details on cost management strategies.
4Insights into R&D progress and pipeline developments.
5Management's outlook on market conditions and competition.